13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001958125
Total reported value
$532.1M
$532.1M
38 檔
32.5%
In Q3 2025, Catalio Capital Management, LP's U.S. equity holdings reached a combined market value of $532.1M, distributed across 38 disclosed stock positions.
Catalio Capital Management, LP executed strategic sector rebalancing during Q3 2025, establishing 16 new positions while fully exiting 15 holdings and trimming 11 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 8.09% | — | +6.42% | |
| 2 | ABBV | Abbvie Inc | Stock-Healthcare | 6.63% | — | — | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.98% | -0.33% | -32.87% | |
| 4 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 5.90% | — | +25.88% | |
| 5 | ASND | Ascendis Pharma A/S | Stock-Other | 5.33% | -6.17% | EXIT | |
| 6 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 5.23% | -4.04% | EXIT | |
| 7 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 4.86% | -9.22% | -10.57% | |
| 8 | BSX | Boston Scientific CORP | Stock-Healthcare | 4.75% | -3.92% | EXIT | |
| 9 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 4.59% | -0.10% | -23.27% | |
| 10 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.59% | -2.97% | EXIT | |
| 11 | NTRA | Natera Inc | Stock-Healthcare | 4.42% | +1.23% | +52.49% | |
| 12 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 3.67% | — | — | |
| 13 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.37% | +0.22% | -2.80% | |
| 14 | QURE | uniQure N.V. | Stock-Other | 3.05% | -1.68% | EXIT | |
| 15 | IRON | Disc Medicine Inc | Stock-Other | 2.65% | +0.55% | +606.20% | |
| 16 | ABVX | Abivax Sa-adr | Stock-Other | 2.54% | -1.10% | EXIT | |
| 17 | SUPN | Supernus Pharmaceuticals Inc | Stock-Healthcare | 2.54% | -0.67% | EXIT | |
| 18 | EXK | Exact Sciences CORP | Stock-Materials | 2.52% | — | — | |
| 19 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 2.46% | -0.57% | EXIT | |
| 20 | ADPT | Adaptive Biotechnologies | Stock-Other | 2.45% | -2.10% | EXIT | |
| 21 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.12% | — | — | |
| 22 | ADMA | Adma Biologics Inc | Stock-Healthcare | 1.86% | — | +20.15% | |
| 23 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.62% | -1.74% | +36.49% | |
| 24 | GUTS | Fractyl Health Inc | Stock-Other | 1.53% | +0.39% | +2333.87% | |
| 25 | GRAL | Grail Inc | Stock-Healthcare | 1.51% | — | — | |
| 26 | TARA | Protara Therapeutic Inc | Stock-Other | 1.21% | -0.26% | -7.72% | |
| 27 | SEPN | Septerna Inc | Stock-Other | 1.02% | +1.89% | — | |
| 28 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.94% | — | — | |
| 29 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.65% | — | — | |
| 30 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.51% | +0.20% | — | |
| 31 | OM | Outset Medical Inc | Stock-Other | 0.31% | +0.01% | -29.03% | |
| 32 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 0.23% | -0.03% | — | |
| 33 | ATAI | AtaiBeckley Inc. | Stock-Other | 0.19% | — | — | |
| 34 | HYPR | Hyperfine Inc | Stock-Other | 0.18% | +0.03% | -9.93% | |
| 35 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.18% | — | -18.12% | |
| 36 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.17% | +0.69% | -2.07% | |
| 37 | PVLA | Palvella Therapeutics Inc | Stock-Other | 0.14% | — | — | |
| 38 | FTH | Faeth Therapeutics Inc | Stock-Other | 0.03% | -0.03% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | +3.3% | +6.42% | Add |
| 2 | SLNOEUR | Soleno Therapeutics Inc | +2.4% | +2.02% | Add |
| 3 | REGN | Regeneron Pharmaceuticals | +1.8% | — | Add |
| 4 | ISRG | Intuitive Surgical Inc | +1.5% | +25.88% | Add |
| 5 | DNTH | Dianthus Therapeutics Inc | +1.5% | -10.57% | Trim |
| 6 | GUTS | Fractyl Health Inc | +1.5% | +2333.87% | Add |
| 7 | ADPT | Adaptive Biotechnologies | +1.3% | -36.63% | Add |
| 8 | QURE | uniQure N.V. | +0.9% | -32.22% | Trim |
| 9 | GPCR | Structure Therapeutics Inc | +0.4% | -2.80% | Trim |
| 10 | KYTX | Kyverna Therapeutics Inc | +0.4% | — | Unchanged |
| 11 | ATAI | AtaiBeckley Inc. | +0.1% | — | Unchanged |
| 12 | TARA | Protara Therapeutic Inc | +0.1% | -7.72% | Add |
| 13 | MGX | Metagenomi Therapeutics Inc | +0.1% | — | Unchanged |
| 14 | HYPR | Hyperfine Inc | +0.1% | -9.93% | Trim |
| 15 | KPTI | Karyopharm Therapeutics Inc | 0% | -2.07% | Trim |
| 16 | OM | Outset Medical Inc | -0.1% | -29.03% | Trim |
| 17 | SEPN | Septerna Inc | -0.4% | — | Trim |
| 18 | SNDX | Syndax Pharmaceuticals Inc | -0.6% | -23.27% | Trim |
| 19 | MLTX | Moonlake Immunotherapeutics | -0.9% | -18.12% | Add |
| 20 | CYTK | Cytokinetics Inc | -1.1% | -24.92% | Trim |
| 21 | ASND | Ascendis Pharma A/S | -2.1% | -19.44% | Trim |
| 22 | BBIO | Bridgebio Pharma Inc | -2.1% | -32.87% | Trim |
| 23 | BDX | Becton Dickinson And Co | — | EXIT | Sold out |
| 24 | ABBV | Abbvie Inc | — | NEW | New buy |
| 25 | SWTXUSD | Springworks Therapeutics Inc | — | EXIT | Sold out |
| 26 | EW | Edwards Lifesciences CORP | — | EXIT | Sold out |
| 27 | BSX | Boston Scientific CORP | — | NEW | New buy |
| 28 | NTRA | Natera Inc | — | NEW | New buy |
| 29 | VCYT | Veracyte Inc | — | EXIT | Sold out |
| 30 | LIVN | LivaNova PLC | — | EXIT | Sold out |
| 31 | IRON | Disc Medicine Inc | — | NEW | New buy |
| 32 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 33 | SUPN | Supernus Pharmaceuticals Inc | — | NEW | New buy |
| 34 | INSP | Inspire Medical Systems Inc | — | EXIT | Sold out |
| 35 | EXK | Exact Sciences CORP | — | NEW | New buy |
| 36 | PHAT | Phathom Pharmaceuticals Inc | — | NEW | New buy |
| 37 | RNAGBP | Avidity Biosciences Inc | — | NEW | New buy |
| 38 | ADMA | Adma Biologics Inc | — | NEW | New buy |
| 39 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 40 | GRAL | Grail Inc | — | NEW | New buy |
| 41 | ✓ | Soleno Therapeutics Inc | — | EXIT | Sold out |
| 42 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 43 | KROS | Keros Therapeutics Inc | — | EXIT | Sold out |
| 44 | VIR | Vir Biotechnology Inc | — | EXIT | Sold out |
| 45 | REPL | Replimune Group Inc | — | EXIT | Sold out |
| 46 | ELDN | Eledon Pharmaceuticals Inc | — | NEW | New buy |
| 47 | ZBIO | Zenas Biopharma Inc | — | EXIT | Sold out |
| 48 | ✓ | Arcutis Biotherapeutics Inc | — | EXIT | Sold out |
| 49 | PVLA | Palvella Therapeutics Inc | — | NEW | New buy |
| 50 | ✓ | Mersana Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Catalio Capital Management, LP reported a total U.S. public equity portfolio value of $532.1M across 38 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, ABBV, BBIO) accounted for 32.5% of total reported equity market value during Q3 2025.
Top New Position Initiated
ABBV
市值: $35.9M
Top Position Liquidated / Trimmed
BDX
前期市值: $46.7M
During Q3 2025, Catalio Capital Management, LP's top holdings by market value included LLY (8.1%)、ABBV (6.6%)、BBIO (6.0%). The largest single position, LLY, represented 8.1% of total portfolio value.
In Q3 2025, Catalio Capital Management, LP made 50 total portfolio adjustments, initiating 16 new buys, adding to 8 positions, trimming 11 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.